The human body starts to produce antibodies against these two structural proteins immediately after the infection. The COVID19 specific immunoglobulins are important immune molecules used for both diagnostic purposes and to develop therapeutic interventions against the virus. To better understand the infection and the virus, antibodies produced by the body against these two structural viral proteins are well studied by scientists as it provides important molecular tools for diagnosis and treatments.
High-quality recombinant Anti-SARS-CoV-2 Spike (S) and (N) proteins, together can help researchers expedite their anti-Covid19 research by providing insights that could help guide the development of safe diagnostic tests, vaccines, and antibody-oriented treatments for the COVID19.
Anti 2019-nCoV N-Protein hIgG Antibody
CoV N-Protein / Nucleocapsid protein is an RNA-binding protein primarily involved in binding to the viral RNA genome during the packaging of viral RNA into a helical ribonucleoprotein or nucleocapsid structure. In addition, N-protein regulates viral RNA synthesis during replication/transcription and modulates host-pathogen interactions, such as actin reorganization, host cell cycle progression, and apoptosis.
The image shows the binding of Anti-2019-nCoV N-Protein Antibody (C19NP-60H) to immobilized 2019-nCoV N-Protein (C19NP-G242H) determined by ELISA using Goat anti-human Fc.
N-Protein is abundantly expressed during infection and antibodies against N-Protein have been detected in confirmed cases of Covid-19. Therefore, N-Protein is a potent antigen that provides the basis for future vaccine and diagnostic kit development.
Anti 2019-nCoV Spike Protein hIgA Antibody
The Spike Glycoprotein (S) of coronavirus belongs to the type I transmembrane protein containing two subunits, S1 and S2, which is also known to be the key component to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2). A receptor-binding domain (RBD) of S1 can recognize the cell surface receptor and the mutation of RBD could cause a higher motility rate.
The image shows binding of Anti-2019-nCoV Spike protein, IgA (C19S1-A60H) to immobilized 2019-nCoV Spike protein RBD (C19SD-G241H) determined by ELISA.
SignalChem is a Canadian biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.
Throughout the years, Signalchem has capitalized on its core expertise in cellular signaling, molecular biology, and protein biochemistry to generate more than 2,000 functional protein products and has established itself as the leader in the industry to produce highly active human recombinant signaling enzymes, especially protein kinases, disease-related mutant kinases, lipid kinases, epigenetic enzymes, ubiquitination-related enzymes, and neurodegenerative disease-related enzymes and proteins.
SignalChem strives to support scientists in academia, pharma, and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.